Predictive and Prognostic Value of Early Disease Progression by PET Evaluation in Advanced Non-Small Cell Lung Cancer

被引：24

作者：

Banna, Giuseppe Luigi ^{[1
]}

Anile, Giuseppe ^{[1
]}

Russo, Giorgio ^{[2
]}

Vigneri, Paolo ^{[3
]}

Castaing, Marine ^{[4
]}

Nicolosi, Maurizio ^{[5
]}

Strano, Salvatore ^{[5
]}

Gieri, Stefania ^{[2
]}

Spina, Rosaria ^{[6
]}

Patane, Domenico ^{[7
]}

Calcara, Giacomo ^{[7
]}

Fraggetta, Filippo ^{[8
]}

Marletta, Francesco ^{[9
]}

Stefano, Alessandro ^{[2
]}

Ippolito, Massimo ^{[10
]}

机构：

[1] Cannizzaro Hosp, Div Med Oncol, Via Messina 829, IT-95126 Catania, Italy

[2] CNR, IBFM, Cefalu, Italy

[3] Univ Catania, Dept Pediat & Med Sci, Catania, Italy

[4] Univ Catania, GF Ingrassia Dept, Catania, Italy

[5] Cannizzaro Hosp, Div Thorac Surg, Catania, Italy

[6] Cannizzaro Hosp, Pharm, Catania, Italy

[7] Cannizzaro Hosp, Dept Radiol, Catania, Italy

[8] Cannizzaro Hosp, Dept Pathol, Catania, Italy

[9] Cannizzaro Hosp, Div Radiotherapy, Catania, Italy

[10] Cannizzaro Hosp, Div Nucl Med, Catania, Italy

来源：

ONCOLOGY | 2017年 / 92卷 / 01期

关键词：

(18)FDG-PET; Advanced non-small cell lung cancer; Early disease evaluation; EORTC criteria; PERCIST criteria; Early progression; Metabolic progression; POSITRON-EMISSION-TOMOGRAPHY; RESPONSE EVALUATION; CHEMOTHERAPY; THERAPY; TUMORS; NSCLC; CRITERIA; TRENDS;

D O I：

10.1159/000448005

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Objective: To assess the predictive and prognostic value of progressive metabolic disease (PMD) by the use of early (18)Fluorodeoxyglucose positron emission tomography ((18)FDG-PET) in patients with clinical stage IV non-small cell lung cancer (NSCLC) treated with first-line chemotherapy. Methods: An (18)FDG-PET performed following the first cycle of chemotherapy (PET-1) was compared with a pretreatment (18)FDG-PET (PET-0) and a computed tomography (CT) scan after the third cycle (CT-3). The primary endpoint was the positive predictive value (PPV) of PMD. Secondary endpoints included the prognostic value of PMD. Results: Eleven of 38 patients (29%) had a PMD by PET-1, and 15 (39%), including all patients with a PMD, experienced a progressive disease by CT-3. The PPV of PMD was 100% according to both the European Organization for Research and Treatment of Cancer (EORTC) criteria and the PET Response Criteria In Solid Tumors (PERCIST) (p value for both, <0.0001). Patients with a PMD by PET-1 had a median overall survival of 7.0 months versus 14.0 months for those without a PMD (p = 0.04, according to the EORTC criteria). Conclusions: Early 18FDG-PET assessment deserves further investigation for the identification of NSCLC patients who do not benefit from first-line chemotherapy. (C) 2016 S. Karger AG, Basel

引用

页码：39 / 47

页数：9

共 30 条

[1] 2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer [J].

Azzoli, Christopher G. ;

Temin, Sarah ;

Aliff, Timothy ;

Baker, Sherman, Jr. ;

Brahmer, Julie ;

Johnson, David H. ;

Laskin, Janessa L. ;

Masters, Gregory ;

Milton, Daniel ;

Nordquist, Luke ;

Pao, William ;

Pfister, David G. ;

Piantadosi, Steven ;

Schiller, Joan H. ;

Smith, Reily ;

Smith, Thomas J. ;

Strawn, John R. ;

Trent, David ;

Giaccone, Giuseppe .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (28) :3825-3831

[2]

Banna GL, 2015, FUTURE ONCOL, V11, P2375, DOI [10.2217/FON.15.172, 10.2217/fon.15.172]

[3] 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease [J].

Besse, B. ;

Adjei, A. ;

Baas, P. ;

Meldgaard, P. ;

Nicolson, M. ;

Paz-Ares, L. ;

Reck, M. ;

Smit, E. F. ;

Syrigos, K. ;

Stahel, R. ;

Felip, E. ;

Peters, S. .

ANNALS OF ONCOLOGY, 2014, 25 (08) :1475-1484

[4] FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0 [J].

Boellaard, Ronald ;

O'Doherty, Mike J. ;

Weber, Wolfgang A. ;

Mottaghy, Felix M. ;

Lonsdale, Markus N. ;

Stroobants, Sigrid G. ;

Oyen, Wim J. G. ;

Kotzerke, Joerg ;

Hoekstra, Otto S. ;

Pruim, Jan ;

Marsden, Paul K. ;

Tatsch, Klaus ;

Hoekstra, Corneline J. ;

Visser, Eric P. ;

Arends, Bertjan ;

Verzijlbergen, Fred J. ;

Zijlstra, Josee M. ;

Comans, Emile F. I. ;

Lammertsma, Adriaan A. ;

Paans, Anne M. ;

Willemsen, Antoon T. ;

Beyer, Thomas ;

Bockisch, Andreas ;

Schaefer-Prokop, Cornelia ;

Delbeke, Dominique ;

Baum, Richard P. ;

Chiti, Arturo ;

Krause, Bernd J. .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2010, 37 (01) :181-200

[5] Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: A systematic review and meta-analysis of individual patient data from 16 randomized controlled trials - NSCLC meta-analyses collaborative group [J].

Burdett, S. ;

Stephens, R. ;

Stewart, L. ;

Tierney, J. ;

Auperin, A. ;

Le Chevalier, T. ;

Le Pechoux, C. ;

Pignon, J. P. ;

Arriagada, R. ;

Higgins, J. ;

Johnson, D. ;

van Meerbeeck, J. ;

Parmar, M. ;

Souhami, R. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (28) :4617-4625

[6] Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study [J].

Cappuzzo, Federico ;

Ciuleanu, Tudor ;

Stelmakh, Lilia ;

Cicenas, Saulius ;

Szczesna, Aleksandra ;

Juhasz, Erzsebet ;

Esteban, Emilio ;

Molinier, Olivier ;

Brugger, Wolfram ;

Melezinek, Ivan ;

Klingelschmitt, Gaelle ;

Klughammer, Barbara ;

Giaccone, Giuseppe .

LANCET ONCOLOGY, 2010, 11 (06) :521-529

[7]

COX DR, 1972, J R STAT SOC B, V34, P187

[8] Chemotherapy response evaluation with 18F-FDG PET in patients with non-small cell lung cancer [J].

de Geus-Oei, Lioe-Fee ;

van der Heijden, Henricus F. M. ;

Visser, Eric P. ;

Hermsen, Rick ;

van Hoorn, Bas A. ;

Timmer-Bonte, Johanna N. H. ;

Willemsen, Antoon T. ;

Pruim, Jan ;

Corstens, Frans H. M. ;

Krabbe, Paul F. M. ;

Oyen, Wim J. G. .

JOURNAL OF NUCLEAR MEDICINE, 2007, 48 (10) :1592-1598

[9] International lung cancer trends by histologic type:: male:female differences diminishing and adenocarcinoma rates rising [J].

Devesa, SS ;

Bray, F ;

Vizcaino, AP ;

Parkin, DM .

INTERNATIONAL JOURNAL OF CANCER, 2005, 117 (02) :294-299

[10] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].

Eisenhauer, E. A. ;

Therasse, P. ;

Bogaerts, J. ;

Schwartz, L. H. ;

Sargent, D. ;

Ford, R. ;

Dancey, J. ;

Arbuck, S. ;

Gwyther, S. ;

Mooney, M. ;

Rubinstein, L. ;

Shankar, L. ;

Dodd, L. ;

Kaplan, R. ;

Lacombe, D. ;

Verweij, J. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247

← 1 2 3 →